The US notes that in 2013 Canada presented again the Combating Counterfeit Products Act to strengthen IPR enforcement, which assigns authority to Canadian customs to confiscate pirated and counterfeit goods at the borders. The United States welcomes Canada’s will to take actions against IPR related issues and counterfeiting industry.
According to the 2014 Special 301 Report, The United States still have concerns about the patents for pharmaceutical products in Canada and especially “ the availability of rights of appeal in Canada’s administrative process for reviewing regulatory approval of pharmaceutical products” and “ the lack of clarity and the impact of the heightened utility requirements for patents that Canadian courts have applied recently”. As per the Report the application of this standard invalidates certain patents of US pharmaceutical companies with the motivation that these products have no industrial application.
The entire report can be found here.
